961 1030
To sum up, this study is a step forward and points to the
great potential of targeted mutation testing in our patients.
However, major efforts are still required to better compre-
hend the biology of bladder cancer and translate this
knowledge into clinical practice.
Conflicts of interest:
The authors have nothing to disclose.
References
[1]
The Cancer Genome Atlas Research Network. Comprehensive mo- lecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22.[2]
Pietzak EJ, Bagrodia A, Cha EK, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 2017;72:952–9.
[3]
Seiler R, Ashab HA, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 2017;72: 544–54.[4]
Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363:1532–43.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 6 0 – 9 6 1
961